Program
sebaloxavir marboxil
Also written as “ZX-7101A”, “ZX-7101A 80mg” and “ZX-7101A and Oseltamivir”.
Its studies are mostly in Influenza, Human, led by Nanjing Zenshine Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Nanjing Zenshine Pharmaceuticals | 121 open or running | phase 3since Jan 16, 2023 | Jan 19, 2022 | Dec 31, 2027phase 3 · NCT07730346 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 19, 2022First study: phase 1 study in Safety IssuesFirst studyNCT05217732 · 66 enrolled · China
- Jan 16, 20232 phase 1 studies in Influenza, HumanNCT05720091, NCT05711797
- Jan 16, 2023Phase 3 study in Influenza, HumanNCT05702489 · 900 enrolled · China
- Jun 13, 20232 phase 1 studiesNCT05949385, NCT05955027
- Sep 12, 2023Phase 1 study in Drug InteractionNCT06057103 · 18 enrolled · China
- Oct 19, 2023Phase 3 study in Respiratory Viral InfectionNCT06099873 · 361 enrolled · China
- Oct 30, 2024Phase 3 study in Influenza, HumanNCT06669351 · 98 enrolled · China
- Feb 13, 2025Phase 1 study in Respiratory Viral InfectionNCT06841926 · 40 enrolled · China
- Jul 24, 2025Phase 3 study in Respiratory Viral InfectionNCT07095257 · 169 enrolled · China
- Jul 23, 2026Phase 3 study in Influenza PreventionNCT07730346 · 858 planned · China
Ahead
- Dec 31, 2027Primary completion: phase 3 study in Influenza PreventionNCT07730346
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07730346Influenza Prevention · China | 3 | Not yet recruiting | Dec 31, 2027 | 858 |
| NCT07095257Respiratory Viral Infection · China | 3 | Completed | Jan 16, 2026 | 169 |
| NCT06841926Respiratory Viral Infection · China | 1 | Completed | Apr 18, 2025 | 40 |
| NCT06669351Influenza, Human · China | 3 | Terminated | Jul 15, 2025 | 98 |
| NCT06099873Respiratory Viral Infection · China | 3 | Completed | Feb 13, 2025 | 361 |
| NCT06057103Drug Interaction · China | 1 | Completed | Dec 5, 2023 | 18 |
| NCT05955027Influenza, Human · China | 1 | Completed | Aug 5, 2023 | 24 |
| NCT05949385Pharmacokinetics · China | 1 | Completed | Sep 23, 2023 | 16 |
| NCT05720091Influenza, Human · China | 1 | Completed | Mar 20, 2023 | 6 |
| NCT05711797Influenza, Human · China | 1 | Completed | Feb 6, 2024 | 16 |
| NCT05702489Influenza, Human · China | 3 | Completed | May 26, 2023 | 900 |
| NCT05217732Safety Issues · China | 1 | Completed | Aug 29, 2022 | 66 |
How it is read
Names in the registry
- “ZX-7101A”, 9 entries
- “ZX-7101A 80mg”, 2 entries
- “ZX-7101A and Oseltamivir”, 2 entries
- “Sebaloxavir marboxil”, 1 entry
- “ZX-7101A for oral suspension”, 1 entry
Codes read as this program: ZX7101A.
Conditions, from the studies’ own filings
- Influenza, Human, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.